Disturbances of cognitive function are considered to largely affect the outcome in patients with schizophrenia. There is much
attention to the role of psychotropic compounds acting on serotonin (5-HT) receptors in ameliorating cognitive deficits of the disease.
Among the 5-HT receptor subtypes, the 5-HT1A receptor is attracting particular interests as a potential target for enhancing cognition,
based on preclinical and clinical evidence. The neural network underlying the ability of 5-HT1A agonists to treat cognitive impairments of
schizophrenia likely includes dopamine, glutamate, and gamma-aminobutyric acid neurons. Recent advances of electrophysiological
measures, such as event-related potentials, have provided insights into facilitative effects on cognition of some atypical antipsychotic
drugs or related compounds acting directly or indirectly on 5-HT1A receptors. These considerations are expected to promote the development
of novel therapeutics for the betterment of functional outcome in people suffering from schizophrenia.
Keywords: Cognitive function, Serotonin, 5-HT1A, prefrontal cortex, glutamate, GABA, electrophysiology, event-related potentials
Rights & PermissionsPrintExport